Gen-Probe (NASDAQ: GPRO) announced today the US Food and Drug Administration (FDA) has approved its PROGENSA® PCA3 (Prostate Cancer gene 3) assay, the first molecular test to help determine the need for repeat prostate biopsies in men who have had a previous negative biopsy.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53530-gen-probe-progensa-pca3-prostate-cancer-psa
With the kick-off of pro football season and September marking National Prostate Cancer Awareness Month, the American Urological Association (AUA) Foundation and the National Football League (NFL) have teamed up for a third year to educate men about prostate health and encourage them to join the “Know Your Stats” campaign. With the support of an increasing number of NFL greats and prostate cancer survivors, the national campaign is focused on turning awareness into action by encouraging men to know their risks and get tested.
To view Multimedia News Release, go to http://www.multivu.com/mnr/51874-aua-foundation-nfl-mike-haynes-know-your-stats-prostate-cancer-awareness
Dendreon Corporation (Nasdaq: DNDN) announced significant milestones that support broad availability for on-label use of PROVENGE® (sipuleucel-T), the first autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer (mCRPC).
To view Multimedia News Release, go to http://www.multivu.com/mnr/50924-dendreon-provenge-cellular-immunotherapy
EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, announced today that new 10 year data from an international registry-based multi-center study shows 83 percent of patients had no biopsy evidence of disease after treatment with Ablatherm® HIFU, supporting the technology as a standard primary treatment for localized prostate cancer. Study results were presented at the American Urological Association (AUA) 2011 Annual Meeting, Washington, D.C.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/edap/49862/
Based on its recent analysis of the prostate cancer diagnosis market, Frost & Sullivan recognizes Hybridyne Technologies, Inc. with the 2010 North American Frost & Sullivan Award for Technology Innovation of the Year.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/frostsullivan/47727/
